Results 171 to 180 of about 112,964 (206)

The roles of copper transporters in cisplatin resistance

Cancer and Metastasis Reviews, 2007
Platinum-based antitumor agents have been effective in the treatments of many human malignancies but the ultimate success of these agents is often compromised by development of drug resistance. One mechanism associated with resistance to platinum drugs is reduced intracellular accumulation owing to impaired drug intake, enhanced outward transport, or ...
Macus Tien, Kuo, Helen H W, Chen, Im-Sook, Song, Niramol, Savaraj, Toshihisa, Ishikawa   +4 more
openaire   +2 more sources

Resistance to cisplatin: How to deal with the problem?

European Journal of Cancer and Clinical Oncology, 1990
SINCE its introduction in clinical practice, cisplatin [cis-diamminedichloroplatinum( II), CDDP] has become one of the most important drugs for treating solid tumors. CDDP-based chemotherapy has clearly improved the response rate for treatment of testicular, ovarian and small cell lung tumors.
J L, Canon, Y, Humblet, M, Symann
openaire   +2 more sources

IN VITRO MODULATION OF CISPLATIN RESISTANCE BY CYTOKINES

Cytokine, 1999
We have previously demonstrated that treatment of wild-type (wt) T98G malignant glioma cells with Cisplatin (CDDP) led to a resistant phenotype. It has been demonstrated that interleukin 1 (IL-1) potentiates the cytotoxic effect of CDDP and that IL-6 decreases cytotoxicity by inhibition of apoptosis in cancer cells. Here we examined the influence of IL-
H, Poppenborg, M M, Knüpfer, H J, Galla, J E, Wolff   +3 more
openaire   +2 more sources

Mechanisms of resistance to cisplatin and alkylating agents

1989
All too often, human solid tumors follow a pattern of initial sensitivity to chemotherapy manifested by a decrease of tumor burden followed by a loss of sensitivity to chemotherapy and by tumor regrowth [1]. This sequence of events is attributed to the presence of a subset of cells in the original tumor that are resistant at the onset of therapy and/or
T C, Hamilton, G M, Lai, M L, Rothenberg, A T, Fojo, R C, Young, R F, Ozols   +5 more
openaire   +2 more sources

Cross-resistance to cisplatin in cells with acquired resistance to copper

Cancer Chemotherapy and Pharmacology, 2004
Cells selected for resistance to cisplatin (DDP) demonstrate cross-resistance to copper (Cu) suggesting one or more common mechanisms of cellular defense. We sought to determine whether cells selected for resistance to Cu are cross-resistant to DDP.Parental HuH7 human hepatoma cells and the CuR27 Cu-resistant subline were compared for sensitivity to Cu
Roohangiz, Safaei, Kuniyuki, Katano, Goli, Samimi, Wiltrud, Naerdemann, Jennifer L, Stevenson, Myriam, Rochdi, Stephen B, Howell   +6 more
openaire   +2 more sources

Metallothioneins and Cisplatin Resistance

1991
Intrinsic and acquired resistance to antineoplastic agents has severely limited our ability to cure solid tumors. Cis-diamminedichloroplatinum (cisplatin) represents one of the most efficacious agents for the treatment of solid tumors especially testicular, ovarian, bladder, and head and neck carcinomas.
openaire   +1 more source

Biochemical and Molecular Mechanisms of Cisplatin Resistance

2002
According to the DISCOVERY Anticancer Drug Screen of the National Cancer Institute in the USA, the inorganic antitumor agent cisplatin(cisdiammine-dichloro-platinum(II); Figure 1) and its analogs fall into at least 13 clustered regions, each reflecting a distinct mechanism of action1. Many of these analogs have not been investigated in depth to unravel
openaire   +2 more sources

Cellular and molecular determinants of cisplatin resistance

European Journal of Cancer, 1998
Cisplatin and carboplatin are among the most active and widely used cytotoxic anticancer drugs. However, the acquisition or presence of resistance significantly undermines the curative potential of these drugs against many malignancies. Multiple potential mechanisms of resistance have been identified at the cellular and molecular levels. Alterations in
openaire   +2 more sources

Cisplatin resistance

Lung Cancer, 1998
S Akiyama, ZS Chen, T Sumizawa, T Furukawa, M Kuwano   +4 more
openaire   +1 more source

Cisplatin resistance reversal with treatment of Citric acid in cisplatin-resistant cell lines

ABSTRACT Gastric cancer (GC) is a prevalent and aggressive malignancy with significant morbidity and mortality rates, posing a major threat to human health globally. While surgery remains the preferred clinical treatment, chemotherapy continues to be the cornerstone for perioperative care, adjuvant therapy, and palliative treatment for ...
Siddhant Chaturvedi, Krishna Venka
openaire   +1 more source